Release time: 2021-05-10 Article source: 特科羅
TechnoDerma Medicines Inc. (m.hhippo.com) announced that the phase I clinical trial of its lead small molecule drug TDM-105795 in topical formulation completed first dosing of two subjects in healthy male subjects with androgenetic alopecia (AGA) at TCR (Therapeutics Clinical Research) in San Diego, in the United States.
TDM-105795 is a small molecule drug at clinical development stage for the treatment of androgenetic alopecia under global intellectual property protection. The phase I clinical study is a fixed-volume topical single-dose administration of the drug in healthy male subjects with androgenetic alopecia (AGA), a multi-center, randomized, double-blind, placebo control, parallel group, and dose escalation design to evaluate the safety, tolerability and pharmacokinetics of TDM-105795.
For the project’s clinical research organization (CRO), Dan Piacquadio MD, CEO of Therapeutics Inc., in San Diego, CA USA said: "We are proud to work together with TechnoDerma on TDM-105795 for the treatment of androgenetic alopecia. This phase I research study is a landmark first-in-man trial which will begin to lay the foundation for the clinical advancement of this novel cutting-edge technology. We are pleased TechnoDerma company is taking on important clinical research, using novel innovative drugs to address unmet needs in important or rare skin indications. It is an honor and privilege that we were chosen us to conduct TDM-105795 clinical trials under the direction of the company. We hope for a successful and smooth clinical research trial."
